Le Lézard9h
Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") on behalf of those who ...
Le Lézard3d
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. . Shareholders who purchased shares ...
William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform
William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...
Fintel on MSN6d
Guggenheim Downgrades Neumora Therapeutics (NMRA)
Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...
Business Insider6d
Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal ...
Business Insider6d
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NMRA
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal ...
NMRA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.
Fintel on MSN9d
Stifel Downgrades Neumora Therapeutics (NMRA)
Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...
JNJ Halts Development of Depression Drug Over Efficacy Concerns
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack ...
BioPharma Dive9d
J&J scraps depression testing for potential blockbuster drug
Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...
Pharmaceutical Technology9d
J&J drops Phase III MDD programme due to lack of efficacy
J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.
BioSpace9d
J&J Axes Late-Stage Depression Trial After Underwhelming Efficacy
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...